Adoptive immunotherapy with virus-specific T cells.

[1]  H. Einsele,et al.  for adoptive transfer into allogeneic stem cell transplant recipients Rapid generation of combined CMV-specific CD4+and CD8+ T-cell lines , 2013 .

[2]  J. Perkins,et al.  ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  G. Lucchini,et al.  Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient , 2011, Bone Marrow Transplantation.

[4]  D. Busch,et al.  Adoptive transfer and selective reconstitution of streptamer‐selected cytomegalovirus‐specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation , 2011, Transfusion.

[5]  E. Thiel,et al.  Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents , 2011, Haematologica.

[6]  S. Mackinnon,et al.  Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  A. Leen,et al.  How I treat adenovirus in hematopoietic stem cell transplant recipients. , 2010, Blood.

[8]  H. Einsele,et al.  Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. , 2010, Blood.

[9]  H. Guchelaar,et al.  Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy. , 2010, Cytotherapy.

[10]  Baoan Chen,et al.  Streptamer-based selection of WT1-specific CD8+ T cells for specific donor lymphocyte infusions. , 2010, Experimental hematology.

[11]  M. Schilham,et al.  Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection , 2010, Haematologica.

[12]  M. Boeckh,et al.  Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. , 2010, Blood.

[13]  J. Stoltz,et al.  Rapid Generation of Full Clinical-Grade Human Antiadenovirus Cytotoxic T Cells for Adoptive Immunotherapy , 2010, Journal of immunotherapy.

[14]  G. Ledderose,et al.  Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. , 2010, Blood.

[15]  D. Brennan,et al.  Human polyoma viruses and disease with emphasis on clinical BK and JC. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[16]  Hao Liu,et al.  Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. , 2010, Blood.

[17]  H. Einsele,et al.  Adoptive transfer of pp 65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation , 2010 .

[18]  T. Brismar,et al.  A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation , 2010, Cancer Immunology, Immunotherapy.

[19]  H. Einsele,et al.  Outcome of treatment of Epstein–Barr virus‐related post‐transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases , 2009, Transplant infectious disease : an official journal of the Transplantation Society.

[20]  E. Jaffe,et al.  Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. , 2009, Blood.

[21]  M. Battegay,et al.  JC Virus-Specific Immune Responses in Human Immunodeficiency Virus Type 1 Patients with Progressive Multifocal Leukoencephalopathy , 2009, Journal of Virology.

[22]  J. Zaia,et al.  Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. , 2008, Blood.

[23]  H. Döhner,et al.  Multimer staining of cytomegalovirus phosphoprotein 65-specific T cells for diagnosis and therapeutic purposes: a comparative study. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  R. Handgretinger,et al.  Clinical Grade Generation of Hexon-specific T Cells for Adoptive T-cell Transfer as a Treatment of Adenovirus Infection After Allogeneic Stem Cell Transplantation , 2008, Journal of immunotherapy.

[25]  D. Lilleri,et al.  Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection , 2008, Haematologica.

[26]  G. Arendt,et al.  Cidofovir in combination with HAART and survival in AIDS-associated progressive multifocal leukoencephalopathy , 2008, Journal of Neurology.

[27]  B. Gazzard,et al.  The risks and incidence of K65R and L74V mutations and subsequent virologic responses. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  H. Heslop,et al.  Adoptive cellular immunotherapy for viral diseases , 2008, Bone Marrow Transplantation.

[29]  D. Busch,et al.  Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. , 2007 .

[30]  H. Bobby Gaspar,et al.  Capture and generation of adenovirus specific T cells for adoptive immunotherapy , 2007, British journal of haematology.

[31]  R. Handgretinger,et al.  Adenovirus infection after allogeneic stem cell transplantation , 2007, Leukemia & lymphoma.

[32]  H. Einsele,et al.  Adoptive immunotherapy of HCMV infection. , 2007, Cytotherapy.

[33]  A. Rojiani,et al.  Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature , 2007, Bone Marrow Transplantation.

[34]  T. Lion,et al.  Safe adoptive transfer of virus‐specific T‐cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation , 2006, British journal of haematology.

[35]  H. Einsele,et al.  Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time , 2005, Bone Marrow Transplantation.

[36]  C. Craddock,et al.  Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA–peptide tetramers , 2005, The Journal of experimental medicine.

[37]  M. Schilham,et al.  Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients. , 2005, The Journal of infectious diseases.

[38]  R. Handgretinger,et al.  Detection of adenovirus‐specific T cells in children with adenovirus infection after allogeneic stem cell transplantation , 2005, British journal of haematology.

[39]  H. Einsele,et al.  Isolation and expansion of human adenovirus-specific CD4+ and CD8+ T cells according to IFN-gamma secretion for adjuvant immunotherapy. , 2004, Experimental hematology.

[40]  S. Rowland-Jones,et al.  Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. , 2002, Blood.

[41]  C. Fegan,et al.  Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. , 2002, Blood.

[42]  D. Busch,et al.  Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer , 2002, Nature Medicine.

[43]  Hans-Georg Rammensee,et al.  Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. , 2002, Blood.

[44]  H. Rammensee,et al.  Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. , 2002, Blood.

[45]  P. Boulanger,et al.  Adenovirus Hexon Protein Is a Potent Adjuvant for Activation of a Cellular Immune Response , 2002, Journal of Virology.

[46]  C. Tournay,et al.  Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. , 2001, Blood.

[47]  T. Tursz,et al.  Immune Response to Recombinant Adenovirus in Humans: Capsid Components from Viral Input Are Targets for Vector-Specific Cytotoxic T Lymphocytes , 2000, Journal of Virology.

[48]  D. Pillay,et al.  Adenovirus infections following haematopoietic cell transplantation: is there a role for adoptive immunotherapy? , 2000, Bone Marrow Transplantation.

[49]  H. Einsele,et al.  Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection , 2000, Bone Marrow Transplantation.

[50]  T. Hibi,et al.  Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation , 2000, Bone Marrow Transplantation.

[51]  K. Wittkowski,et al.  Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. , 1995, Blood.

[52]  K. Cornetta,et al.  Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation. , 1994, Blood.

[53]  M. Ladanyi,et al.  Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. , 1994, The New England journal of medicine.

[54]  S. Riddell,et al.  Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. , 1991, Blood.

[55]  J. Manischewitz,et al.  Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. , 1982, The New England journal of medicine.